Funded Tech Companies
Solu Therapeutics
Solu Therapeutics, based in Boston, received equity investments from Eli Lilly and Company, Astellas Venture Capital and Alexandria Venture Investments.
Company Overview
Company Name
Solu Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate disease-driving cells. Solu Therapeutics, a precision-medicine company, is developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets providing the capability to develop next generation medicines that harness the power of biologics with the vast target binding space of small molecules. Unique characteristics of CyTaC platform molecules include: (i) unlocking new tumor-associated antigens to eliminate cancer cells, (ii) depleting pathogenic immune cells, and (iii) extending the half-life of small molecule antagonists and agonists.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
4/9/2025
Financing History
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Donabedian
Chief Medical Officer
Ewelina Morawa
Co-Founder
Brandon Turunen
Company Investors
- Eli Lilly and Company
- Astellas Venture Capital
- Alexandria Venture Investments
- Biovision Ventures
- Pappas Capital
- Longwood Fund
- Sante Ventures
- DCVC Bio
- The Leukemia & Lymphoma Society
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs